Isolated left‐sided pulmonary edema caused by alemtuzumab (Campath®) during kidney transplantation

Summary Alemtuzumab is a novel anti‐CD‐52 monoclonal antibody for immunosuppression. Although cost effective and efficacious, alemtuzumab is not without risk. Interestingly, intraoperative complications caused by alemtuzumab have rarely been reported. We describe a case of intraoperative pulmonary edema following administration of alemtuzumab. A 22‐year‐old man underwent kidney transplantation and received alemtuzumab intraoperatively. To provide better surgical exposure for transplantation, the operation table was tilted to the right. At the end of 3.5‐h uneventful procedure, a sudden oxygen desaturation was noted after the bed was flattened. The postoperative chest X‐ray showed opacification of the entire left lung field. After 4 days of bi‐level positive airway pressure treatment, the lung field was cleared. This case is unique in that pulmonary edema developed during surgery after administration of alemtuzumab, and that the edema developed only in the nondependent lung. Transplant anesthesiologists should be aware of the risk of this complication with these novel anti‐CD‐52 monoclonal antibodies.